Spinout deal offers dialysis hope

Published: 8 May 2018

Invizius, a spinout company whose technology could save the lives of thousands of dialysis patients, has secured £500,000 from Mercia Fund Managers, in the first investment since Mercia and the University formed a partnership agreement in November 2017.

Invizius stems from years of research by biologist Dr Andy Herbert and his team, who believe they have found a way to reduce the risk of cardiovascular disease among patients undergoing long-term dialysis. The investment will allow the company to build its team and take the product to the next stage of development in preparation for clinical trials.

The University signed a partnership agreement with Mercia in November 2017, which included hosting Mercia staff on campus and Mercia earmarking funding for investment in technologies and business opportunities developed by the University.

It is wonderful to see the first fruits of this new and exciting collaboration, demonstrating the value of having commercial partners hosted on campus by the University. The investment reflects the great potential of this technology to change many people’s lives, which is typical of the innovation emerging from our research.

Hugh Edmiston, Director of Corporate Services, University of Edinburgh


Despite improvements in dialysis therapy, cardiovascular disease remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of that for the general population. The patient’s immune system sees the dialysis filter as a foreign body, creating inflammation that damages the cardiovascular system over time.

Invizius’s H-Guard™ product is a powerful anti-inflammatory used as a ‘primer’ to coat the filter surface which, when mixed with the patient’s blood, makes the surface seem less foreign to the patient’s immune system. Unlike some other proposed solutions, H-Guard does not shut down the immune system but instead effectively ‘hides’ the device from it to prevent an immune response.

While the first product is aimed at kidney dialysis, there is also potential to use the technology with other devices or procedures such as catheters, stents, organ transplants and vascular grafts.

Invizius is led by Chief Executive Officer Richard Boyd, who previously founded VueKlar Cardiovascular, with Dr Herbert as Chief Technology Officer. The team has spent six years developing the technology with support from world-leading dialysis manufacturers, Kidney Research UK, and £600,000 from Scottish Enterprise’s High Growth Spin Out Programme.

Edinburgh Innovations, which manages industry engagement for the University of Edinburgh, has supported the researchers throughout the commercialisation process, which started with their novel scientific findings and included the recent launch of the spinout company.

I’m delighted to see this substantial investment in a University spinout company, whose work holds such promise for many patients. It’s a perfect example of how partnerships can enhance the University’s impact, and Edinburgh Innovations looks forward to working with Mercia and our researchers to identify and support further such opportunities.

Dr George Baxter, Chief Executive Officer, Edinburgh Innovations

Richard Boyd said, "Mercia’s ability to back and help develop life sciences businesses from spinout through to commercialisation “makes them an ideal partner for Invizius”.

Dr Nicola Broughton, Head of Universities at Mercia, said Invizius was an “excellent choice for our first investment under our partnership with the University”. She added: “This technology could revolutionise kidney dialysis and, with three million patients worldwide, has the potential to save countless lives. The funding will take the company one step closer to bringing it to market.”

Source: Edinburgh Innovations

 

Share

Latest tweets

follow us @MidlothScience

The University of Edinburgh

  • Old College
  • South Bridge
  • Edinburgh EH8 9YL

General Enquiries:

T: +44 (0)131 650 1000

Email us